SION
$35.84
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF).
Recent News
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares
This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing.
Assessing Sionna Therapeutics (SION) Valuation As Premium P/B Meets Cooling Share Price Momentum
Sionna Therapeutics (SION) has drawn attention after recent trading, with the share price closing at $38. For investors tracking performance, returns over the past week, month and past 3 months show mixed moves. See our latest analysis for Sionna Therapeutics. That recent softness in the 1 month share price return of 12.44% and 3 month share price return of 12.78%, despite a 1 year total shareholder return of around 2.6x, suggests some of the earlier enthusiasm has cooled as investors...
Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim Summit
Sionna Therapeutics (NASDAQ:SION) used its presentation at the Guggenheim Emerging Outlook Biotech Summit 2026 to outline its strategy to develop next-generation cystic fibrosis (CF) therapies centered on NBD1 stabilization, and to preview multiple mid-2026 clinical catalysts. Company background an
Sionna Therapeutics Chief Legal Officer Caps Off Strong 2025 with Sale of Over 10,000 Shares
After having a successful IPO less than a year ago, this biotech innovator had notable insider transactions to close out 2025.
Assessing Sionna Therapeutics (SION) Valuation After Recent Share Price Swings And Premium P/B Multiple
What Sionna Therapeutics’ Recent Price Move Means for Investors Sionna Therapeutics (SION) shares recently closed at $39.25, with the stock showing mixed short term moves, including a 7.24% gain over the past day and a negative return over the past month. See our latest analysis for Sionna Therapeutics. Looking beyond the latest move, Sionna Therapeutics has a 90 day share price return of 33.91% but a 30 day share price return of 8.23%. This suggests recent momentum has cooled after a...